DRKS00023486招募中不适用
Functional Immuno-monitoring of Cystic Fibrosis Patients
Institute of Clinical and Experimental Trauma Immunology, University Hospital Ulm0 个研究点目标入组 25 人开始时间: 2020年11月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Age at least 18 years; indication for Kaftrio therapy; homozygous deltaF508 mutation or compound heterozygous for deltaF508 and a minimal function mutation
排除标准
- •acute infection, fever or surgical intervention within the last 7 days; blood transfusion within the last 3 months; immunosuppressive therapy; systemic antibiotic therapy within the last 3 days
研究者
相似试验
已完成
不适用
Building a picture of inflammatory arthritis in cystic fibrosisCystic Fibrosis Associated ArthropathyMusculoskeletal DiseasesISRCTN34533467niversity Hospital South Manchester75
已完成
不适用
A Novel Assay to Quantify Treatment Response in Cystic Fibrosis (CF)Cystic FibrosisNCT01626157Milene Saavedra122
已完成
不适用
Interactive Video Game Responses in Cystic FibrosisCystic FibrosisNCT03229213Pontificia Universidade Católica do Rio Grande do Sul55
已完成
不适用
Observation of the treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infection with ColiFin 1Mio I.E. or ColiFin 2Mio I.E.Chronic infection with Pseudomonas aeruginosaCystic fibrosisE84B96.5Pseudomonas (aeruginosa) as the cause of diseases classified to other chaptersCystic fibrosisDRKS00009540PARI Pharma GmbH32
已完成
不适用
COVID-19 Antibody Responses in Cystic FibrosisCoronavirus diseaseCOVID-19 infection100474381002160510010613NL-OMON56611Erasmus MC, Universitair Medisch Centrum Rotterdam50